Objective The lack of randomized controlled trials (RCTs) in pulmonary fibrosis in systemic
sclerosis (SSc) has hampered an evidence‐based approach to treatment. This RCT was …

Objective To develop and validate revised classification criteria for granulomatosis with
polyangiitis (GPA). Methods Patients with vasculitis or comparator diseases were recruited into …

Objective To develop and validate revised classification criteria for eosinophilic granulomatosis
with polyangiitis (EGPA). Methods Patients with vasculitis or comparator diseases were …

Objective To develop and validate classification criteria for microscopic polyangiitis (MPA).
Methods Patients with vasculitis or comparator diseases were recruited into an international …

Objective To develop and validate new classification criteria for Takayasu arteritis (TAK).
Methods Patients with vasculitis or comparator diseases were recruited into an international …

Rationale: The impact of coronavirus disease (COVID-19) on patients with interstitial lung
disease (ILD) has not been established. Objectives: To assess outcomes in patients with ILD …

Objective To determine the prognostic value of pulmonary function test (PFT) trends at 1 and
2 years in interstitial lung disease (ILD) associated with systemic sclerosis (SSc). Methods …

Objective Connective tissue growth factor (CTGF; CCN2) is overexpressed in systemic
sclerosis (SSc) and has been hypothesized to be a key mediator of the pulmonary fibrosis …

Background Interstitial lung disease is a known complication of rheumatoid arthritis, with a
lifetime risk of developing the disease in any individual of 7·7%. We aimed to assess the safety…

Objective. Biomarkers of progression of interstitial lung disease (ILD) are needed to allow
early therapeutic intervention in patients with scleroderma-associated disease (SSc-ILD). …